2026-05-13T12:06:38-05:00 2025-12-31 990 2025-01-01 834634227 LYDIAN ACCELERATOR % Rohan Seth LYDI 6503845866 548 MARKET ST STE PMB 38841 San Francisco CA 94104 ROHAN SETH President 6503845866 2026-05-13 2025 2025-03-06 01:10:19Z X Rohan Seth 548 MARKET ST Ste PMB 38841 San Francisco CA 94104 221722 false X WWW.LYDIANACCELERATOR.ORG X 2019 CA Our mission is to bring an end to the long tail of genetic disease 5 5 0 5 0 0 21876 29379 0 241924 192343 0 263800 221722 137339 135421 0 0 0 548 150420 118384 287759 253805 -23959 -32083 4773460 4741377 0 4773460 4741377 To invest in scientific and translational research of personalized genetic treatments for children impacted by severe genetic disease. false false 252895 CONTINUED A DRUG DISCOVERY PROGRAM FOR A NOVEL ALLELE SELECTIVE ANTISENSE OLIGONUCLEOTIDE MOLECULE TO KNOCKDOWN THE MUTANT KCNQ2 CAUSING DEVELOPMENT AND EPILEPTIC ENCEPHALOPATHY. 252895 true true false false false false false false false false false false false false false false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false false false true 3 0 true 0 false false false false false false false false X 5 5 false false false false false false false true true false false true true true true true true false false false CA X ROHAN SETH 6503845866 548 MARKET ST San Francisco CA 94104 X ROHAN SETH President 40.00 0.00 X X 0 0 0 COREY LONG Board Member 0.50 0.00 X 0 0 0 CINNAMON CHU Treasurer 1.00 0.00 X X 0 0 0 AMBER BAHL Board Member 0.50 0.00 X 0 0 0 ROHAN DANG Secretary 1.00 0.00 X X 0 0 0 0 0 0 0 false false false 28907 472 29379 192343 192343 0 221722 0 0 192343 135421 135421 20 20 290 290 548 548 2379 2379 52 52 Research Supplies 4820 4820 Sponsored Research 103675 103675 Research Contract Srvcs 6600 6600 253805 252895 362 548 39172 67631 4734288 4658746 15000 4773460 4741377 0 0 X 4773460 4741377 4773460 4741377 4773460 4741377 -32083 0 X false false false X 4972471 18723 26259 21876 29380 5068709 4972471 18723 26259 21876 29380 5068709 5068709 91 32605 231042 241924 192343 698005 5766714 0.87900 0.91400 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED The Jackson Labratory 600 MAIN ST Bar Harbor ME 04609 010211513 501c3 14104 DNA Research NLorem Foundation 2888 Loker Ave E Carlsbad CA 92010 843288113 501c3 100000 Advanced ASO Research McLaughlin Research Instit 1520 23rd St S Great Falls MT 59405 810459235 501c3 6062 Genetic Research Unravel CSNK2A1 Fund 1395 Marsten Rd Burlingame CA 94010 824220939 501c3 14000 Nuero Devel Gene Research KCNQ Alliance 3700 Quebec Street Denver CO 80207 471810644 501c3 650 KCNQ Research Part VI Line 11b FORM 990 IS REVIEWED BY ALL BOARD MEMBERS PRIOR TO FILING. Part VI Line 19 see above Part VI, Sec B, Line 12C: THE CONFLICT OF INTEREST POLICY COVERS DIRECTORS, PRINCIPAL OFFICERS, AND Part VI, Sec B, Line 12C: MEMBERS OF A COMMITTEE WITH GOVERNING BOARD DELEGATED POWERS, WHO HAVE A Part VI, Sec B, Line 12C: DIRECT OR INDIRECT FINANCIAL INTEREST. IN CONNECTION WITH ANY ACTUAL OR Part VI, Sec B, Line 12C: POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE Part VI, Sec B, Line 12C: EXISTENCE OF THE FINANCIAL INTEREST AND BE GIVEN THE OPPORTUNITY TO Part VI, Sec B, Line 12C: DISCLOSE ALL MATERIAL FACTS TO THE DIRECTORS CONSIDERING THE PROPOSED Part VI, Sec B, Line 12C: TRANSACTION OR ARRANGEMENT. AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND Part VI, Sec B, Line 12C: ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, Part VI, Sec B, Line 12C: HE/SHE SHALL LEAVE THE BOARD MEETING WHILE THE DETERMINATION OF A CONFLICT Part VI, Sec B, Line 12C: OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD MEMBERS SHALL Part VI, Sec B, Line 12C: DECIDE IF A CONFLICT OF INTEREST EXISTS. THE CHAIR OF THE BOARD SHALL, IF Part VI, Sec B, Line 12C: APPROPRIATE, APPOINT A DISINTERESTED PERSON OR GOVERNING COMMITTEE TO Part VI, Sec B, Line 12C: INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER Part VI, Sec B, Line 12C: EXERCISING DUE DILIGENCE, THE BOARD SHALL DETERMINE WHETHER THE CORPORATION Part VI, Sec B, Line 12C: CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR Part VI, Sec B, Line 12C: ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT Part VI, Sec B, Line 12C: OF INTEREST. COVERED PERSONS ARE REQUIRED TO REVIEW AND CERTIFY COMPLIANCE Part VI, Sec B, Line 12C: WITH THE POLICY ON AN ANNUAL BASIS. PART VI, SECTION C, LINE 19: THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND PART VI, SECTION C, LINE 19: FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST WHEN PART VI, SECTION C, LINE 19: REQUIRED BY FEDERAL OR STATE LAW.